Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
In a new guest blog post – Dr Owen Jones, winner of the Amsbio 2024 ISSCR Travel Grant, reflects on his work developing and applying human stem cell–derived retinal organoid models for disease research and therapeutic discovery. Amsbio is delighted to have played a supporting role in Dr Jones scientific endeavors.
Revolutionising Imaging: The Power and Promise of LAFOV PET and the NPIP Network
Webinar 1 | Introduction to Long Axial Field of View (LAFOV) PET: Capabilities and Transformational Potential
(12/01/26 4pm GMT)
Speakers:
Dr Simon R. Cherry, University of California, Davis, and King’s College London
Dr Antonis Kalemis, Siemens Healthineers
Stewart Young, United Imaging
The United Kingdom Health Security Agency (UKHSA) is a system leader for health security; taking action internationally to strengthen global health security, providing trusted advice to government and the public and reducing inequalities in the way different communities experience and are impacted by infectious disease, environmental hazards, and other threats to health.
We are currently accepting applications with a view to schedule interviews early in January 2026.
tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle.
Join an innovative team as a Digital Marketing Executive, driving multi-channel marketing campaigns and supporting business growth in a dynamic research and technology environment.
Key Responsibilities:
- Develop, implement, and optimise digital marketing campaigns across PPC, SEO, email, and social media platforms.
- Analyse campaign performance using analytics tools, providing actionable insights to improve ROI.
- Create engaging content for websites, blogs, and social media to enhance brand presence.
Vilnius - December 11, 2025 – VUGENE, LLC an intelligent bioinformatics company providing pioneering multi-omics solutions for biomedical research, today announced a strategic collaboration with Inotiv, Inc. (NASDAQ: NOTV) a leading Contract Research Organization (CRO). The collaboration is designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum. For VUGENE it also represents an important entry into the pharmaceutical services market.
About Us
Our guiding mission is to identify and investigate cellular and molecular mechanisms that cause and control inflammation and to relate these findings to human health and disease.
We are interdisciplinary in nature; by bringing together different disciplines, we will accelerate our understanding of the common as well as the unique mechanisms that contribute to inflammation-related pathologies.
OMass Therapeutics is a biotechnology company based in Oxford discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs.